Biogen Heute minus??? - 500 Beiträge pro Seite
eröffnet am 10.07.00 18:51:03 von
neuester Beitrag 12.07.00 00:30:36 von
neuester Beitrag 12.07.00 00:30:36 von
Beiträge: 24
ID: 180.568
ID: 180.568
Aufrufe heute: 0
Gesamt: 804
Gesamt: 804
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 11:52 | 2931 | |
| vor 1 Stunde | 2243 | |
| gestern 22:26 | 1414 | |
| heute 14:11 | 1353 | |
| 08.05.24, 11:56 | 1305 | |
| vor 52 Minuten | 1264 | |
| heute 13:44 | 1059 | |
| vor 1 Stunde | 946 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.772,85 | +0,46 | 131 | |||
| 2. | 3. | 0,2170 | +3,33 | 125 | |||
| 3. | Neu! | 8,2570 | +96,67 | 108 | |||
| 4. | 4. | 156,46 | -2,31 | 103 | |||
| 5. | 14. | 5,7540 | -2,18 | 56 | |||
| 6. | 2. | 0,2980 | -3,87 | 50 | |||
| 7. | 5. | 2,3720 | -7,54 | 49 | |||
| 8. | 7. | 6,8000 | +2,38 | 38 |
Feedback!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Die Zahlen am Dienstag werden nochmal sehr Schlecht ausfallen. Man munkelt in Insiderkreisen das hier nicht alles nach Vorstellung der Oberen Herren gelaufen ist.
Stimme dir zu no limit.
Die letzten Zahlen waren eine Katastrophe. Morgen ziehen die den Kurs wieder heftig nach unten. Aber langfristig kann am Mi oder Do kaufen.
Die letzten Zahlen waren eine Katastrophe. Morgen ziehen die den Kurs wieder heftig nach unten. Aber langfristig kann am Mi oder Do kaufen.
Die Säcke von Prudential Ser. haben Biogen
heute runtergestuft!
Letzte Woche noch ein STRONG BUY (weiß nicht von wem)
und heute das.
Ob die nochmal billig rein wollten....
Alte Leier: moniert wird die Ein-Produkt-Pipeline
von Biogen.
Mfg
heute runtergestuft!
Letzte Woche noch ein STRONG BUY (weiß nicht von wem)
und heute das.
Ob die nochmal billig rein wollten....
Alte Leier: moniert wird die Ein-Produkt-Pipeline
von Biogen.
Mfg
Wurde heute von prudential Securities herabgestuft.
so long
Deggi
so long
Deggi
Trading Spotlight
So So Gestern rauf und Heute runtergestuft,das alte lied also wieder
naja die können mich mal
las sie liegen bis sie schwarz werden,und mein Konto auch
und danke für die Anwohrten
Tatonka
naja die können mich mal
las sie liegen bis sie schwarz werden,und mein Konto auch
und danke für die Anwohrten
Tatonka
wer weiß wann heute Zahlen kommen, Kurs relativ stabil
Was solls, langfristig top
Was solls, langfristig top
hmh, von 73 auf 69???? ist da jemand in Erwartung neg. Nachrichten
Ja, ich denke schon! Allein die Zurueckstufung von Prudential Securities laesst nichts gutes erwarten. Die Analysten gaben laut N-TV an, dass die Absatzzahlen von Avonex, dem Hauptstandbein, ruecklaeufig waeren. Dennoch ist heute der Wert an der Nasdaq leicht angezogen. Bis jetzt haben wir in den ad hocs immer noch nicht die neuen Quartalszahlen bekommen. Gestern wurden in Deutschland nach Abrutschen des Kurses sehr grosse Stuecke gehandelt, da dachte ich: vielleicht wissen die grossen ja mehr als wir! Habe mir dennoch heute nach leichter Erholung den bisherigen Gewinn gesichert. Ich denke der Bericht von Biogen wird hinter den Erwartungen zurueckbleiben und der Kurs morgen deutlich fallen.
C.
C.
Hab ich gerade auf EarningsWhispers.com gefunden
The consensus estimate for Biogen (BGEN) is $0.42 but there is concern among some of the analysts that Avonex sales will be less than expected and that the company will fall short of the estimates for the second quarter in a row. This concern was reiterated yesterday in a report to Prudential Securities` clients. Overall, though, the expectations are for Biogen to surprise by a penny or two with revenues beating the $188 million consensus expectation. The Earnings Whisper Ò number is $0.43 and the revenue whisper number is $192 million.However, the real expectation is not for the company`s earnings or revenues, but rather the new products for the end of the year. The analysts are expecting to get details of the products during the earnings conference this evening. You may listen to the conference call at http://tm.intervu.net/template/smirror/ivtemplates/ccbn/ipc-… beginning at 5:00 PM ET today.
Die Bekanntgabe der neuen Zahlen wird also um 23.00 Uhr stattfinden, puenktlich zum Ende des Sekundenhandels....C.
The consensus estimate for Biogen (BGEN) is $0.42 but there is concern among some of the analysts that Avonex sales will be less than expected and that the company will fall short of the estimates for the second quarter in a row. This concern was reiterated yesterday in a report to Prudential Securities` clients. Overall, though, the expectations are for Biogen to surprise by a penny or two with revenues beating the $188 million consensus expectation. The Earnings Whisper Ò number is $0.43 and the revenue whisper number is $192 million.However, the real expectation is not for the company`s earnings or revenues, but rather the new products for the end of the year. The analysts are expecting to get details of the products during the earnings conference this evening. You may listen to the conference call at http://tm.intervu.net/template/smirror/ivtemplates/ccbn/ipc-… beginning at 5:00 PM ET today.
Die Bekanntgabe der neuen Zahlen wird also um 23.00 Uhr stattfinden, puenktlich zum Ende des Sekundenhandels....C.
auf NTV :0,42cent erwartet,,,,,043cent erreicht
na allso,, es wird doch nochwas
wurde posetiv an der Nasdag aufgenommen
dan los..... go go go
Tatonka
na allso,, es wird doch nochwas
wurde posetiv an der Nasdag aufgenommen
dan los..... go go go
Tatonka
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Die Redaktion WO schreibt
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
Biogen steigert im 2Q den Gewinn je Aktie auf 47 Cent
auf NTW heist es 43Cent
was ist nun richtig????
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Toll gleich 10 mal
das board spinnt
das board spinnt
habe auch 47 cents als nachricht, hmm
47 cents stimmt!
Hier zwei Quellen, die erste stammt vom Biogen-press release
FOR IMMEDIATE RELEASE
BIOGEN REPORTS SECOND QUARTER 2000 RESULTS
Record Revenues and Number of AVONEX Patients Reported
Cambridge, MA (July 11, 2000) -- Biogen, Inc. (NASDAQ/BGEN) today reported
financial results for the second quarter of 2000. For the three months ended
June 30, 2000, the Company reported net income of $72,060,000, or $0.47 per
share. Revenues for the quarter were $230,514,000. For the second quarter of
last year, the Company reported net income of $43,388,000, or $0.28 per share,
based on revenues of $188,929,000. Net income and diluted earnings per share
for the second quarter of 2000 included gains from sales of certain securities
of approximately $8,681,000 (on a pre-tax basis), or $0.04 per diluted share
(net of tax).
James C. Mullen, Biogen’s President and Chief Executive Officer, said, "The
market for MS treatments continues to expand, led by AVONEX®, with its
unsurpassed convenience and efficacy. AVONEX remains the leader both in terms
of number of patients and sales volume. More than 90,000 patients are on
therapy worldwide. Total AVONEX sales in the second quarter 2000 were
$190,009,000, up from $145,852,000 in second quarter 1999, an increase of more
than 30 percent.
"We believe this growth will be reinforced by the CHAMPS data, which again
proved the importance of AVONEX by showing that it significantly delayed the
onset of clinically definite MS in people at risk for MS. There is a very clear
message behind the continuing strength of this drug: AVONEX is the best choice
for people with MS who want to maintain their daily functioning.
“During the quarter, we continued to make good progress on our clinical
pipeline. Patient accrual for two Phase III trials with AMEVIVE™, both
involving patients with chronic plaque psoriasis, is well ahead of schedule.
Other accomplishments included the topping off of a large-scale manufacturing
facility in Research Triangle Park, North Carolina, and the opening of Biogen’s
first European manufacturing operation, a packaging facility in The Netherlands.
This expansion reinforces our leadership position in the biopharmaceutical
industry in terms of manufacturing capability and our confidence in the future.”
In addition to historical facts, this press release contains forward-looking
statements that involve risks and uncertainties that could cause actual results
to differ materially from those reflected in the forward-looking statements.
Reference is made in particular to statements regarding the anticipated growth
in AVONEX sales and outlook for AVONEX and the anticipated effect of new data
related to AVONEX. Factors which could cause actual results related to AVONEX
growth and outlook to differ from the Company’s current expectations include,
without limitation, the impact of competitive products on AVONEX sales, any
slowdown or failure in obtaining or maintaining market acceptance for AVONEX in
key markets worldwide, any unexpected negative results from clinical trials, any
failure of the FDA to approve labeling changes related to new data and the other
risks and uncertainties associated with drug development and commercialization
described in the Company’s periodic reports filed with the Securities and
Exchange Commission. Reference is made in particular to the “Outlook” section
of Management’s Discussion and Analysis of Financial Condition and Results of
Operation in the Company’s 1999 Annual Report on Form 10-K and in quarterly
reports on Form 10-Q.
Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company’s revenues are generated from worldwide sales of
AVONEX® for treatment of relapsing forms of multiple sclerosis, and from the
worldwide sales by licensees of a number of products, including alpha interferon
and hepatitis B vaccines and diagnostic products. Biogen’s research and
development activities are focused on novel products for multiple sclerosis,
inflammatory, respiratory, kidney and cardiovascular diseases and in
developmental biology and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen’s Homepage on
the World Wide Web at http://www.biogen.com.
AVONEX® (Interferon beta-1a) is a registered trademark of Biogen, Inc. AMEVIVE™
(Recombinantly Engineered LFA-3/IgG1 Human Fusion Protein) is a trademark of
Biogen, Inc. AVONEX is approved in the U.S. and in most other countries around
the world for the treatment of relapsing forms of multiple sclerosis.
die zweite von CBS
CAMBRIDGE, Mass. (CBS.MW) -- Biogen reported higher
second-quarter earnings Tuesday, driven by sales of its flagship product,
the multiple sclerosis drug Avonex.
The company said (BGEN: news, msgs) said profit
rose to $72.1 million, or 47 cents a share, up from
$43.4 million, or 28 cents in the same quarter a
year ago. Results include a 4-cent-a-share gain
from the sale of securities.
Analysts expected the company to earn 42 cents in
the quarter, according to First Call.
Revenue rose to $230.5 million from $188.9
million. Total Avonex sales in the second quarter
rose 30 percent to $190 million from $145.9
million in the year-ago quarter.
Biogen shares rose 2 to 72 in Instinet trading after
the market closed.
SG Cowen analyst Eric Schmidt said revenue came
in ahead of forecasts. “The top line is strong --at
the upper end of Street expectations,” he said.
The higher-than-expected revenue increase will no
doubt be welcome news for investors, who’ve seen
the stock face pressure in recent months.
Some analysts say Biogen is going to have to take aggressive steps to
regain confidence in its ability to generate strong future growth. The
company’s new CEO, James Mullen, has said he’s committed to
spending aggressively to develop products that reduce its dependence on
Avonex.
naja, mal sehen
47 cents stimmt!
Hier zwei Quellen, die erste stammt vom Biogen-press release
FOR IMMEDIATE RELEASE
BIOGEN REPORTS SECOND QUARTER 2000 RESULTS
Record Revenues and Number of AVONEX Patients Reported
Cambridge, MA (July 11, 2000) -- Biogen, Inc. (NASDAQ/BGEN) today reported
financial results for the second quarter of 2000. For the three months ended
June 30, 2000, the Company reported net income of $72,060,000, or $0.47 per
share. Revenues for the quarter were $230,514,000. For the second quarter of
last year, the Company reported net income of $43,388,000, or $0.28 per share,
based on revenues of $188,929,000. Net income and diluted earnings per share
for the second quarter of 2000 included gains from sales of certain securities
of approximately $8,681,000 (on a pre-tax basis), or $0.04 per diluted share
(net of tax).
James C. Mullen, Biogen’s President and Chief Executive Officer, said, "The
market for MS treatments continues to expand, led by AVONEX®, with its
unsurpassed convenience and efficacy. AVONEX remains the leader both in terms
of number of patients and sales volume. More than 90,000 patients are on
therapy worldwide. Total AVONEX sales in the second quarter 2000 were
$190,009,000, up from $145,852,000 in second quarter 1999, an increase of more
than 30 percent.
"We believe this growth will be reinforced by the CHAMPS data, which again
proved the importance of AVONEX by showing that it significantly delayed the
onset of clinically definite MS in people at risk for MS. There is a very clear
message behind the continuing strength of this drug: AVONEX is the best choice
for people with MS who want to maintain their daily functioning.
“During the quarter, we continued to make good progress on our clinical
pipeline. Patient accrual for two Phase III trials with AMEVIVE™, both
involving patients with chronic plaque psoriasis, is well ahead of schedule.
Other accomplishments included the topping off of a large-scale manufacturing
facility in Research Triangle Park, North Carolina, and the opening of Biogen’s
first European manufacturing operation, a packaging facility in The Netherlands.
This expansion reinforces our leadership position in the biopharmaceutical
industry in terms of manufacturing capability and our confidence in the future.”
In addition to historical facts, this press release contains forward-looking
statements that involve risks and uncertainties that could cause actual results
to differ materially from those reflected in the forward-looking statements.
Reference is made in particular to statements regarding the anticipated growth
in AVONEX sales and outlook for AVONEX and the anticipated effect of new data
related to AVONEX. Factors which could cause actual results related to AVONEX
growth and outlook to differ from the Company’s current expectations include,
without limitation, the impact of competitive products on AVONEX sales, any
slowdown or failure in obtaining or maintaining market acceptance for AVONEX in
key markets worldwide, any unexpected negative results from clinical trials, any
failure of the FDA to approve labeling changes related to new data and the other
risks and uncertainties associated with drug development and commercialization
described in the Company’s periodic reports filed with the Securities and
Exchange Commission. Reference is made in particular to the “Outlook” section
of Management’s Discussion and Analysis of Financial Condition and Results of
Operation in the Company’s 1999 Annual Report on Form 10-K and in quarterly
reports on Form 10-Q.
Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company’s revenues are generated from worldwide sales of
AVONEX® for treatment of relapsing forms of multiple sclerosis, and from the
worldwide sales by licensees of a number of products, including alpha interferon
and hepatitis B vaccines and diagnostic products. Biogen’s research and
development activities are focused on novel products for multiple sclerosis,
inflammatory, respiratory, kidney and cardiovascular diseases and in
developmental biology and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen’s Homepage on
the World Wide Web at http://www.biogen.com.
AVONEX® (Interferon beta-1a) is a registered trademark of Biogen, Inc. AMEVIVE™
(Recombinantly Engineered LFA-3/IgG1 Human Fusion Protein) is a trademark of
Biogen, Inc. AVONEX is approved in the U.S. and in most other countries around
the world for the treatment of relapsing forms of multiple sclerosis.
die zweite von CBS
CAMBRIDGE, Mass. (CBS.MW) -- Biogen reported higher
second-quarter earnings Tuesday, driven by sales of its flagship product,
the multiple sclerosis drug Avonex.
The company said (BGEN: news, msgs) said profit
rose to $72.1 million, or 47 cents a share, up from
$43.4 million, or 28 cents in the same quarter a
year ago. Results include a 4-cent-a-share gain
from the sale of securities.
Analysts expected the company to earn 42 cents in
the quarter, according to First Call.
Revenue rose to $230.5 million from $188.9
million. Total Avonex sales in the second quarter
rose 30 percent to $190 million from $145.9
million in the year-ago quarter.
Biogen shares rose 2 to 72 in Instinet trading after
the market closed.
SG Cowen analyst Eric Schmidt said revenue came
in ahead of forecasts. “The top line is strong --at
the upper end of Street expectations,” he said.
The higher-than-expected revenue increase will no
doubt be welcome news for investors, who’ve seen
the stock face pressure in recent months.
Some analysts say Biogen is going to have to take aggressive steps to
regain confidence in its ability to generate strong future growth. The
company’s new CEO, James Mullen, has said he’s committed to
spending aggressively to develop products that reduce its dependence on
Avonex.
naja, mal sehen
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 64 | ||
| 45 | ||
| 33 | ||
| 19 | ||
| 18 | ||
| 16 | ||
| 15 | ||
| 15 | ||
| 13 | ||
| 10 |
| Wertpapier | Beiträge | |
|---|---|---|
| 9 | ||
| 8 | ||
| 7 | ||
| 7 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 6 | ||
| 5 | ||
| 5 |
